Skip to main content
Aker BioMarine logo

Aker BioMarine — Investor Relations & Filings

Ticker · AKBM ISIN · NO0010886625 LEI · 549300V34T6VWDSYWE64 OL Agriculture, forestry and fishing
Open in API
Filings indexed 508 across all filing types
Latest filing 2023-02-15 Investor Presentation
Country NO Norway
Listing OL AKBM

About Aker BioMarine

https://www.akerbiomarine.com/

Aker BioMarine is a biotechnology innovator that sustainably harvests Antarctic krill to develop and supply krill-derived ingredients. The company's core business focuses on producing ingredients for the human health and nutrition markets, including nutraceuticals and dietary supplements. It also serves the aquaculture and animal feed sectors with specialized products. Aker BioMarine leverages its vertically integrated supply chain and scientific research to create a portfolio of products that extends to agricultural biostimulants and pharmaceutical applications. The company is committed to sustainable operations and the scientific validation of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Aker BioMarine ASA - results fourth quarter 2022
Investor Presentation Classification · 99% confidence The document text explicitly states it covers the "FORTH QUARTER AND FULL-YEAR 2022" and includes detailed financial tables for Q4 2022 vs Q4 2021, and YTD 2022 vs YTD 2021. It contains a full Profit and Loss statement, Balance Sheet statement, segment performance breakdowns (Ingredients, Brands), and operational highlights for the full year. This comprehensive nature, covering a full fiscal year and detailed financial statements, strongly indicates an Annual Report, which corresponds to the 10-K filing type in the US context, or the equivalent comprehensive annual filing. Although the text is unaudited for Q4 2022, the inclusion of the full-year audited figures from the prior year (YTD 2021 Audited) and the comprehensive scope points to the annual reporting requirement.
2023-02-15 Norwegian
Aker BioMarine ASA - results fourth quarter 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Fourth quarter report 2022' and contains comprehensive financial statements, operational reviews, and segment-specific performance data for Aker BioMarine. It provides detailed financial tables (Net sales, Gross margin, Operating profit, etc.) for the quarter and the full year. Since it is a comprehensive financial report for a period shorter than a full fiscal year (Q4) and contains substantive financial data, it is classified as an Interim/Quarterly Report. Q4 2022
2023-02-15 Norwegian
Aker BioMarine ASA - results fourth quarter 2022
Earnings Release Classification · 98% confidence The document explicitly states it reports 'results fourth quarter 2022' and provides key financial metrics (Revenues, Adjusted EBITDA) and operational highlights for that period. This content structure—key figures followed by management commentary and an announcement of a webcast/Q&A session—is characteristic of an Earnings Release (ER). It is not a comprehensive annual report (10-K) or a detailed interim report (IR), but rather the initial announcement of the period's results. Q4 2022
2023-02-15 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for various corporate events throughout 2022 and 2023, including 'Quarterly Report', 'Half-yearly Report', 'Annual Report', and 'Annual General Meeting'. It is not the report itself, but rather an announcement detailing *when* reports and meetings will occur. Since it is an announcement about the publication schedule of future reports, it fits best under the general category for regulatory announcements that don't fit a specific report type, which is Regulatory Filings (RNS), or potentially Report Publication Announcement (RPA) if it were announcing the immediate release of a specific report. Given it is a forward-looking calendar, RNS is the most appropriate general regulatory announcement category.
2023-01-20 English
Aker BioMarine ASA – a product mainly containing Superba krill oil approved in South Korea
Environmental & Social Information Classification · 99% confidence The document is a short announcement dated December 21, 2022, detailing a regulatory approval received by Aker BioMarine from the Ministry of Food and Drug Safety (MFDS) in South Korea regarding a product containing Superba krill oil. It discusses regulatory changes and future expectations. This type of specific, material, non-financial update that is not a standard periodic report (like 10-K or IR) and doesn't fit into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), is best classified as a general Regulatory Filing (RNS), as it is a stock exchange announcement concerning regulatory compliance and market access. Given its nature as a specific regulatory update, RNS is the most appropriate fallback.
2022-12-21 English
Aker BioMarine ASA – Mandatory notification of trade
Director's Dealing Classification · 99% confidence The document text is titled 'KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar («primærinnsider») og deres nærstående' (KRT-1500 Form for reporting transactions carried out by persons discharging managerial responsibilities ('primary insiders') and their close associates). This structure, detailing transactions by insiders (CEO Matts Eirik Johansen in this case), including transaction type (Kjøp/Buy), instrument (Aksje/Share), price, volume, and date, is characteristic of mandatory insider trading disclosure forms, often mandated by regulations like MAR in Europe. This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2022-11-15 Norwegian

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.